Literature DB >> 19018980

Features and consequences of untreated type 1 autoimmune hepatitis.

Albert J Czaja1.   

Abstract

BACKGROUND/AIM: The existence of a mild form of autoimmune hepatitis that does not require treatment remains controversial. The aim of this study was to determine the existence, characteristics and outcome of this form.
METHODS: Untreated patients with type 1 autoimmune hepatitis who did not satisfy pre-established criteria for severe disease were identified retrospectively and compared with treated patients.
RESULTS: Twenty-one of 282 patients (7%) who were evaluated during a 32-year period did not receive corticosteroid treatment. These asymptomatic patients constituted 15% of 137 patients who satisfied similar criteria for mild disease. Untreated patients with mild disease were indistinguishable from 116 treated patients with mild disease, and they differed from 145 treated patients with severe disease only by the pre-established features that defined disease severity. The eight untreated patients with follow-up assessments satisfied remission criteria less commonly than treated patients with mild or severe disease during 77+/-31 months of observation (12 vs 63%, P=0.006), and they had a lower 10-year survival (67 vs 98%, P=0.01). Four patients did improve spontaneously albeit short of remission criteria and remained well for 28+/-15 months (range, 5-73 months). Four patients worsened during 125+/-51 months of observation (range, 32-239 months), including two of three patients with cirrhosis who died of liver failure.
CONCLUSIONS: Mild type 1 autoimmune hepatitis does exist, and it may be as frequent as severe disease. Untreated patients with mild disease can improve spontaneously, but there are no confident indices by which to identify this subgroup and justify withholding treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018980     DOI: 10.1111/j.1478-3231.2008.01904.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  21 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

Review 2.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

3.  Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

Review 4.  Management of Difficult Cases of Autoimmune Hepatitis.

Authors:  Craig Lammert; Veronica M Loy; Kiyoko Oshima; Samer Gawrieh
Journal:  Curr Gastroenterol Rep       Date:  2016-02

Review 5.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 6.  Challenges in the diagnosis and management of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-09       Impact factor: 3.522

Review 7.  Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management.

Authors:  Syed Rizvi; Samer Gawrieh
Journal:  Drugs Aging       Date:  2018-07       Impact factor: 3.923

Review 8.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 9.  Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids.

Authors:  Marta Casal Moura; Rodrigo Liberal; Hélder Cardoso; Ana Maria Horta E Vale; Guilherme Macedo
Journal:  World J Hepatol       Date:  2014-06-27

10.  Treatment of autoimmune liver disease: current and future therapeutic options.

Authors:  Palak J Trivedi; Gideon M Hirschfield
Journal:  Ther Adv Chronic Dis       Date:  2013-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.